The Pennant Group is set to announce its Q4 2025 earnings, with market expectations predicting a 45.8% year-over-year revenue growth. The company has a history of surpassing analyst expectations and has seen its share price increase by 6.6% in the last month, in contrast to the broader healthcare segment’s underperformance. The average analyst price target for The Pennant Group is $37.50, significantly higher than its current share price of $32.56.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
The Pennant Group Earnings: Q4 2025 Results & Analysis - News and Statistics
The Pennant Group is set to announce its Q4 2025 earnings, with market expectations predicting a 45.8% year-over-year revenue growth. The company has a history of surpassing analyst expectations and has seen its share price increase by 6.6% in the last month, in contrast to the broader healthcare segment’s underperformance. The average analyst price target for The Pennant Group is $37.50, significantly higher than its current share price of $32.56.